糖尿病黄斑水肿：发病机制及治疗进展_West China Medical Journal

Authors：

杨晓璐 , 许迅

Corresponding author：

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 杨晓璐,许迅. 糖尿病黄斑水肿：发病机制及治疗进展. West China Medical Journal, 2009, 24(2): 499-504. doi: Copy

1.	Ciulla T，Amador A，Zinman B.Diabetic retinopathy and diabetic macular edema[J].Diabetes Care，2003，26(9)：2653-2664..
2.	Thompson MJ，Ip MS.Diabetic macular edema：A review of past，present，and future therapies[J].Int Ophthalmol Clin，2004，44(4)：51-67..
3.	Klein R，Klein BE，Moss SE，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.ⅩⅤ.The longterm incidence of macular edema[J].Ophthalmology，1995，102(1)：7-16..
4.	王宁，许迅，邹海东，等.上海北新泾社区2型糖尿病患者黄斑水肿患病情况调查[J].中华眼科杂志，2007，43(7)：626-630..
5.	Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema.Early Treatment Diabetic Retinopathy Study report number 1[J].Arch Ophthalmol，1985，103(12)：1796-1806..
6.	Bringmann A，Reichenbach A，Wiedemann P.Pathomechanisms of cystoid macular edema[J].Ophthalmic Res，2004，36：241-249..
7.	Aiello LP，Northrup J M，Keyt BA，et al.Hypoxic regulation of vascular endothelial growth factor in retinal cells[J].Arch Ophthalmol，1995，113(12)：1538-1544..
8.	Lam DS，Chan CK，Mohamed S，et al.Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema：sixmonth outcomes[J].Ophthalmology，2007，114(12)：21627..
9.	Yanoff M，Fine BS，Brucker AJ.Pathology of human cystoid macular edema[J].Surv Ophthalmol，1984，28 Suppl：505511.
10.	Stefansson E，Landers MB.How does vitrectomy affect diabetic macular edema?[J]Am J Ophthalmol，2006，141(5)：984..
11.	Lewis H，Abrams G W，Blumekranz M S，et al.Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction[J].Ophthalmology，1992，99(5)：753-759..
12.	Walton KA，Meyer CH，Harkrider CJ，et al.Agerelated changes in vitreous mobility as measured by video B scan ultrasound[J].Exp Eye Res，2002，74(2)：173-180..
13.	Chew EY，Klein ML，Ferris FL 3rd，et al.ETDRS Research Group：association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy：Early Treatment of Diabetic Retinopathy Study (ETDRS) Report No.22[J].Arch Ophthalmol，1996，114(9)：1079-1084..
14.	Klein R，Klein BE，Moss SE，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy，ⅩⅦ：the 14year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes[J].Ophthalmology，1998，105(10)：1801-1815..
15.	Ronald K.Prevention of visual loss from diabetic retinopathy[J].Surv Ophthalmol，2002，47(Suppl 2)：246252..
16.	Girach A，LundAndersen H.Diabetic macular edema：a clinical overview[J].Int J Clin Pract，2007，61(1)：88-97..
17.	Romero P，Baget M,Mendez I,et al.Diabetic macular edema and its relationship to renal microangiopathy：a sample of type Ⅰ diabetes mellitus patients in a 15year followup study[J].J Diabetes Complications，2007，21(3)：172-180..
18.	Diabetes Control and Complications Trial Research Group.Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial[J].Ophthalmology，1995，102(4)：647661..
19.	UKPDS.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group[J].Lancet，1998，352(9131)：837-853..
20.	Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes：UKPDS 38[J].BMJ，1998，317(7160)：703-712..
21.	Matthews DR，Stratton IM，Aldington SJ.Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus：UKPDS 69[J].Arch Ophthalmol，2004，122(11)：1631-1640..
22.	Miyamoto K，Khosrof S，Bursell SE，et al.Prevention of leukostasis and vascular leakage in streptozotocininduced diabetic retinopathy via intercellular adhesion molecule1 inhibition[J].Proc Natl Acad Sci USA，1999，96(19)：10836-10841..
23.	Joussen AM，Murata T，Tsujikawa A，et al.Leukocytemediated endothelial cell injury and death in the diabetic retina[J].Am J Pathol，2001，158(1)：147-152..
24.	Joussen AM，Poulaki V，Mitsiades N，et al.Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNFα suppression[J].FASEBJ，2002，16(3)：438-440..
25.	Chew EY，Klein ML，Ferris FL，et al.Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy.ETDRS Report 22[J].Arch Ophthalmol，1996，114(9)：1079-1084..
26.	ChKlein BE，Moss SE，Klein R，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.ⅩⅢ.Relationship of serum cholesterol to retinopathy and hard exudate[J].Ophthalmology，1991，98(8)：12611265..
27.	Owdhury TA，Hopkins D，Dodson PM，et al.The role of serum lipids in exudative diabetic maculopathy：is there a place for lipidlowering therapy?[J]Eye，2002，16(6)：689-693..
28.	Lyons TJ，Jenkins AJ，Zheng D，et al.Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort[J].Invest Ophthalmol Vis Sci，2004，45(3)：910-918..
29.	Ucgun NI，Yildirim Z，Kilic N，et al.The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients[J].Ann NY Acad Sci，2007，1100：213-217..
30.	Gardner TW，Antonetti DA.A prize catch for diabetic retinopathy[J].Nat Med，2007，13(2)：131-132..
31.	Bandello F，Lanzetta P，Menchini U.When and how to do a grid laser for diabetic macular edema[J].Doc Ophthalmol，1999，97(34)：415-419..
32.	Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema.Early Treatment Diabetic Retinopathy Study Report Number 1[J].Arch Ophthalmol，1985，103：17961806..
33.	Early Treatment Diabetic Retinopathy Study Research Group：Early photocoagulation for diabetic retinopathy：ETDRS Report No.9[J].Ophthalmology，1991，98(Suppl 5)：766-785..
34.	William E.Benson.Diabetic Retinopathy.In：Duane’s Clinical Ophthalmology.[Book on CDROM].Lippincott Williams & Wilkins Publishers，2004：Chap 30..
35.	Meyer CH.Current treatment approaches Diabetic macular edema[J].Ophthalmologica，2007，221(2)：118-131..
36.	Recchia FM，Ruby AJ.Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persisitent diabetic macular edema[J].Am J Ophthalmol，2005，139(3)：447-454..
37.	Lewis H，Abrams GW，Blumekranz MS，et al.Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction[J].Ophthalmology，1992，99(5)：753-759..
38.	Stefaniotou MI，Aspiotis MV，Kalogeropoulos CD.Vitrectomy results for diffuse DME with and without ILM removal[J].Eur J Ophthalmol，2004，14(2)：137-143..
39.	Dillinger P，Mester U.Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema[J].Graefes Arch Clin Exp Ophthalmol，2004，242(8)：630-637..
40.	Kralinger MT，Pedri M，Kralinger F.Longterm outcome after vitrectomy for diabetic macular edema[J].Ophthalmologica，2006，220(3)：147-152..
41.	Jahn CE，Tpfner von Schutz K，Richter J，et al.Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy[J].Ophthalmologica，2004，218：378-384..
42.	Stolba U，Binder S，Gruber D，et al.Vitrectomy for persistent diffuse diabetic macular edema[J].Am J Ophthalmol，2005，140(2)：295-301..
43.	Gandorfer A，Messmer EM，Ulbig MW，et al.Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane[J].Retina，2000，20(2)：126-133..
44.	Ikeda T，Sato K，Katano T，et al.Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema and detached posterior hyaloid[J].Retina，2000，20(2)：220-222..
45.	La Heij EC，Hebdrikse F，Kessels AGH，et al.Vitrectomy results in diabetic macular oedema without evident vitreomacular traction[J].Graefes Arch Clin Exp Ophthalmol，2001，239(4)：264-270..
46.	Gotzaridis EV，Markou A，Zdenek G.Management of diabetic retinopathy：an overview[J].Hormones(Athens)，2004，3(2)：92-99..
47.	Yanyali A，Horozoglu F，Celik E，et al.Longterm outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema[J].Retina，2007，27(5)：557-566..
48.	Avci R，Kaderli B，Avci B，et al.Pars plana vitrectomy and removal of the internal limiting membrane in the treatment of chronic macular oedema[J].Graefes Arch Clin Exp Ophthalmol，2004，242(10)：845-852..
49.	Kamura Y，Sato Y，Isomae T，et al.Effects of internal limiting membrane peeling in vitrectomy on diabetic cystoid macular edema patients[J].Jpn J Ophthalmol，2005，49(4)：297-300..
50.	Ikagawa H，Yoneda M，Iwaki M，et al.Chemical toxicity of indocyanine green damages retinal pigment epithelium[J].Invest Ophthalmol Vis Sci，2005,46(7)：2531-2539..
51.	Yamamoto T，Hitani K，Sato Y，et al.Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema[J].Ophthalmologica，2005，219(4)：206-213..
52.	Jonas JB，Kreissig I，Sofker A，et al.Intravitreal injection of triamcinolone for diffuse diabetic macular edema[J].Arch Ophthalmol，2003，121(1)：57-61..
53.	Martidis A，Duker JS，Greenberg PB，et al，Baumal C.Intravitreal triamcinolone for refractory diabetic macular edema[J].Am J Ophthalmol，2002，109(5)：920-927..
54.	姚毅，王志军，姜荔，等.玻璃体内注射曲安奈德治疗糖尿病性弥漫性黄斑水肿的初步观察[J].中华眼底病杂志，2005，21(4)：217-219..
55.	Bandello F，Polito A，Pognuz DR，et al.Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy[J].Arch Ophthalmol，2006，124(5)：643-650..
56.	Zacks DN，Johnson MW.Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy[J].Retina，2005，25(2)：135-140..
57.	Smithen LM，Ober MD，Maranan L，et al.Intravitreal triamcinolone acetonide and intraocular pressure[J].Am J Ophthalmol，2004，138(5)：740-743..
58.	Quiram PA，Gonzales CR，Schwartz SD.Severe steroidinduced glaucoma following intravitreal injection of triamcinolone acetonide[J].Am J Ophthalmol，2006，141(3)：580-582..
59.	Kaushik S，Gupta V，Gupta A，et al.Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion[J].Am J Ophthalmol，2004，137(4)：758-760..
60.	Thompson JT.Cataract formation and other complications of intravitreal triamcinolone for macular edema[J].Am J Ophthalmol，2006，141(4)：629-637..
61.	Kuppermann BD，Blumenkranz MS，Haller JA，et al.Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema[J].Arch Ophthalmol，2007，125(3)：309-317..
62.	Tilton RG，Kawamura T，Chang KC，et al.Vascular dysfunction induced by elevated glucose levels in rats mediated by vascular endothelial growth factor[J].J Clin Invest，1997，99(9)：2192-2202..
63.	Ferrara N.Vascular endothelial growth factor：basic science and clinical progress[J].Endocr Rev，2004，25(4)：581-611..
64.	Tolentino MJ，Miller JW，Gragoudas ES，et al.Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate[J].Ophthalmology，1996，103(11)：18201828..
65.	Tolentino MJ，McLeod DS，Taomoto M.Pathologic features of vascular endothelial growth factorinduced retinopathy in the nonhuman primate[J].Am J Ophthalmol，2002，133(3)：373-385..
66.	Adamis AP，Shima DT，Tolentino MJ，et al.Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate[J].Arch Ophthalmol，1996，114(1)：6671..
67.	Aiello LP，Pierce EA，Foley ED，et al.Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor(VEGF)using soluble VEGFreceptor chimeric proteins[J].Proc Natl Acad Sci USA，1995，92(23)：10457-10461..
68.	Jorge R，Costa RA，Calucci D，et al.Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)[J].Retina，2006，26(9)：1006-1013..
69.	Ferrara N，Houck KA，Jakeman LB，et al.The vascular endothelial growth factor family of polypeptides[J].J Cell Biochem，1991，47(3)：211-218..
70.	Spaide RF，Fisher YL.Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage[J].Retina,2006，26(3)：275-278..
71.	Michels S，Rosenfeld PJ，Puliafito CA，et al.Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration. Twelveweek results of an uncontrolled openlabel clinical study[J].Ophthalmology，2005，112(6)：1035-1047..
72.	Avery RL，Pieramici DJ，Rabena MD，et al.Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration[J].Ophthalmology，2006，113(3)：363-372..
73.	Iturralde D，Spaide RF，Meyerle CB.Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion：a shortterm study[J].Retina，2006，26(3)：279-284..
74.	Diabetic Retinopathy Clinical Research Network (DRCR.net)，a phase 2 randomized clinical trial of intravitreal Bevacizumab for diabetic macular edema[J].Ophthalmology，2007，114(10)：1860-1867..
75.	Rosenfeld PJ，Brown DM，Heier JS，et al，MARINA Study Group.Ranibizumab for neovascular agerelated macular degeneration[J].N Engl J Med，2006，355(14)：14191431..
76.	Brown DM，Kaiser PK，Michels M，et al，ANCHOR Study Group.Ranibizumab versus verteporfin for neovascular agerelated macular degeneration[J]. N Engl J Med，2006，355(14)：1432-1444..
77.	Chun DW，Heier JS，Topping TM，et al.A pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema[J]. Ophthalmology，2006，113(10)：1706-1712..
78.	Nguyen QD，Tatlipinar S，Shah SM，et al.Vascular endothelial growth factor is a critical stimulus for diabetic macular edema[J].Am J Ophthalmol，2006，142(6)：961-969..
79.	Koya D，King GL.Protein kinase C activation and the development of diabetic complications[J].Diabetes，1998，47(6)：859-866..
80.	Nagpala P，Malik AB，Vuong PT，et al.Protein kinase Cb1 overexpression augments phorbol esterinduced increase in endothelial permeability[J].J Cell Physiol，1996，166：249-255..
81.	Xia P，Aiello LP，Ishii H.Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C，its isoforms，and endothelial cell growth[J].J Clin Invest，1996，98：2018-2026..
82.	Xu X，Qi Z，Xin X，et al.Bloodretinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocininduced diabetic rats[J].Curr Eye Res，2004，28(4)：251256..
83.	Zhu Q，Xu X，Xia X，et al.Role of protein kinase C on the alteration of retinal endothelin1 in streptozotocininduced diabetic rats[J].Exp Eye Res，2005，81(2)：200-206..
84.	Jirousek MR，Gillig JR，Gonzalez CM，et al.(S)13[(dimethylamino)methyl]10，11，14，15tetrahydro4，9：16，21dimetheno1H，13Hdibenzo[e，k]pyrrolo[3，4h][1，4，13]oxadiazacyclohexadecene1，3(2H)dione(LY333531)and related analogues：isozyme selective inhibitors of protein kinase C[J].J Med Chem，1996，39(14)：26642671..
85.	The PKCDRS Study Group，The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy：initial results of the protein kinaseC inhibitor diabetic retinopathy study (PKCDRS) multicenter randomized clinicaltrial[J].Diabetes，2005，54(7)：2188-2197..
86.	PKCDRS2 Group，Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy[J].Ophthalmology，2006，113(12)：2221-2230..
87.	The PKCDMES Study Group，Effect of ruboxistaurin in patients with diabetic macular edema：thirtymonth results of the randomized PKCDMES clinical trial[J].Arch Ophthalmol，2007，125(3)：318-324..
88.	Strm C，Sander B，Klemp K，et al.Effect of ruboxistaurin on bloodretinal barrier permeability in relation to severity of leakage in diabetic macular edema[J].Invest Ophthalmol Vis Sci，2005，46(10)：38553888..
89.	The PKCDRS Study Group.The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy：initial results of the protein kinase C β inhibitor Diabetic Retinopathy Study (PKCDRS) multicentre randomized clinical trial[J].Diabetes，2005，54(7)：2188-2197..
90.	Aiello LP，Vignati L，Sheetz MJ.Effect of ruboxistaurin (RBX) on diabetic macular edema (DME) and visual loss：Metaanalysis of the PKCDRS and PKCDRS2[J].Diabetes，2006，55(S1)：54..
91.	Schwartz SG，Flynn HW.Pharmacotherapies for diabetic retinopathy：present and future[J].Exp Diabetes Res，2007，2007：52487..

1. Ciulla T，Amador A，Zinman B.Diabetic retinopathy and diabetic macular edema[J].Diabetes Care，2003，26(9)：2653-2664..
2. Thompson MJ，Ip MS.Diabetic macular edema：A review of past，present，and future therapies[J].Int Ophthalmol Clin，2004，44(4)：51-67..
3. Klein R，Klein BE，Moss SE，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.ⅩⅤ.The longterm incidence of macular edema[J].Ophthalmology，1995，102(1)：7-16..
4. 王宁，许迅，邹海东，等.上海北新泾社区2型糖尿病患者黄斑水肿患病情况调查[J].中华眼科杂志，2007，43(7)：626-630..
5. Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema.Early Treatment Diabetic Retinopathy Study report number 1[J].Arch Ophthalmol，1985，103(12)：1796-1806..
6. Bringmann A，Reichenbach A，Wiedemann P.Pathomechanisms of cystoid macular edema[J].Ophthalmic Res，2004，36：241-249..
7. Aiello LP，Northrup J M，Keyt BA，et al.Hypoxic regulation of vascular endothelial growth factor in retinal cells[J].Arch Ophthalmol，1995，113(12)：1538-1544..
8. Lam DS，Chan CK，Mohamed S，et al.Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema：sixmonth outcomes[J].Ophthalmology，2007，114(12)：21627..
9. Yanoff M，Fine BS，Brucker AJ.Pathology of human cystoid macular edema[J].Surv Ophthalmol，1984，28 Suppl：505511.
10. Stefansson E，Landers MB.How does vitrectomy affect diabetic macular edema?[J]Am J Ophthalmol，2006，141(5)：984..
11. Lewis H，Abrams G W，Blumekranz M S，et al.Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction[J].Ophthalmology，1992，99(5)：753-759..
12. Walton KA，Meyer CH，Harkrider CJ，et al.Agerelated changes in vitreous mobility as measured by video B scan ultrasound[J].Exp Eye Res，2002，74(2)：173-180..
13. Chew EY，Klein ML，Ferris FL 3rd，et al.ETDRS Research Group：association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy：Early Treatment of Diabetic Retinopathy Study (ETDRS) Report No.22[J].Arch Ophthalmol，1996，114(9)：1079-1084..
14. Klein R，Klein BE，Moss SE，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy，ⅩⅦ：the 14year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes[J].Ophthalmology，1998，105(10)：1801-1815..
15. Ronald K.Prevention of visual loss from diabetic retinopathy[J].Surv Ophthalmol，2002，47(Suppl 2)：246252..
16. Girach A，LundAndersen H.Diabetic macular edema：a clinical overview[J].Int J Clin Pract，2007，61(1)：88-97..
17. Romero P，Baget M,Mendez I,et al.Diabetic macular edema and its relationship to renal microangiopathy：a sample of type Ⅰ diabetes mellitus patients in a 15year followup study[J].J Diabetes Complications，2007，21(3)：172-180..
18. Diabetes Control and Complications Trial Research Group.Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial[J].Ophthalmology，1995，102(4)：647661..
19. UKPDS.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group[J].Lancet，1998，352(9131)：837-853..
20. Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes：UKPDS 38[J].BMJ，1998，317(7160)：703-712..
21. Matthews DR，Stratton IM，Aldington SJ.Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus：UKPDS 69[J].Arch Ophthalmol，2004，122(11)：1631-1640..
22. Miyamoto K，Khosrof S，Bursell SE，et al.Prevention of leukostasis and vascular leakage in streptozotocininduced diabetic retinopathy via intercellular adhesion molecule1 inhibition[J].Proc Natl Acad Sci USA，1999，96(19)：10836-10841..
23. Joussen AM，Murata T，Tsujikawa A，et al.Leukocytemediated endothelial cell injury and death in the diabetic retina[J].Am J Pathol，2001，158(1)：147-152..
24. Joussen AM，Poulaki V，Mitsiades N，et al.Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNFα suppression[J].FASEBJ，2002，16(3)：438-440..
25. Chew EY，Klein ML，Ferris FL，et al.Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy.ETDRS Report 22[J].Arch Ophthalmol，1996，114(9)：1079-1084..
26. ChKlein BE，Moss SE，Klein R，et al.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.ⅩⅢ.Relationship of serum cholesterol to retinopathy and hard exudate[J].Ophthalmology，1991，98(8)：12611265..
27. Owdhury TA，Hopkins D，Dodson PM，et al.The role of serum lipids in exudative diabetic maculopathy：is there a place for lipidlowering therapy?[J]Eye，2002，16(6)：689-693..
28. Lyons TJ，Jenkins AJ，Zheng D，et al.Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort[J].Invest Ophthalmol Vis Sci，2004，45(3)：910-918..
29. Ucgun NI，Yildirim Z，Kilic N，et al.The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients[J].Ann NY Acad Sci，2007，1100：213-217..
30. Gardner TW，Antonetti DA.A prize catch for diabetic retinopathy[J].Nat Med，2007，13(2)：131-132..
31. Bandello F，Lanzetta P，Menchini U.When and how to do a grid laser for diabetic macular edema[J].Doc Ophthalmol，1999，97(34)：415-419..
32. Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema.Early Treatment Diabetic Retinopathy Study Report Number 1[J].Arch Ophthalmol，1985，103：17961806..
33. Early Treatment Diabetic Retinopathy Study Research Group：Early photocoagulation for diabetic retinopathy：ETDRS Report No.9[J].Ophthalmology，1991，98(Suppl 5)：766-785..
34. William E.Benson.Diabetic Retinopathy.In：Duane’s Clinical Ophthalmology.[Book on CDROM].Lippincott Williams & Wilkins Publishers，2004：Chap 30..
35. Meyer CH.Current treatment approaches Diabetic macular edema[J].Ophthalmologica，2007，221(2)：118-131..
36. Recchia FM，Ruby AJ.Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persisitent diabetic macular edema[J].Am J Ophthalmol，2005，139(3)：447-454..
37. Lewis H，Abrams GW，Blumekranz MS，et al.Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction[J].Ophthalmology，1992，99(5)：753-759..
38. Stefaniotou MI，Aspiotis MV，Kalogeropoulos CD.Vitrectomy results for diffuse DME with and without ILM removal[J].Eur J Ophthalmol，2004，14(2)：137-143..
39. Dillinger P，Mester U.Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema[J].Graefes Arch Clin Exp Ophthalmol，2004，242(8)：630-637..
40. Kralinger MT，Pedri M，Kralinger F.Longterm outcome after vitrectomy for diabetic macular edema[J].Ophthalmologica，2006，220(3)：147-152..
41. Jahn CE，Tpfner von Schutz K，Richter J，et al.Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy[J].Ophthalmologica，2004，218：378-384..
42. Stolba U，Binder S，Gruber D，et al.Vitrectomy for persistent diffuse diabetic macular edema[J].Am J Ophthalmol，2005，140(2)：295-301..
43. Gandorfer A，Messmer EM，Ulbig MW，et al.Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane[J].Retina，2000，20(2)：126-133..
44. Ikeda T，Sato K，Katano T，et al.Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema and detached posterior hyaloid[J].Retina，2000，20(2)：220-222..
45. La Heij EC，Hebdrikse F，Kessels AGH，et al.Vitrectomy results in diabetic macular oedema without evident vitreomacular traction[J].Graefes Arch Clin Exp Ophthalmol，2001，239(4)：264-270..
46. Gotzaridis EV，Markou A，Zdenek G.Management of diabetic retinopathy：an overview[J].Hormones(Athens)，2004，3(2)：92-99..
47. Yanyali A，Horozoglu F，Celik E，et al.Longterm outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema[J].Retina，2007，27(5)：557-566..
48. Avci R，Kaderli B，Avci B，et al.Pars plana vitrectomy and removal of the internal limiting membrane in the treatment of chronic macular oedema[J].Graefes Arch Clin Exp Ophthalmol，2004，242(10)：845-852..
49. Kamura Y，Sato Y，Isomae T，et al.Effects of internal limiting membrane peeling in vitrectomy on diabetic cystoid macular edema patients[J].Jpn J Ophthalmol，2005，49(4)：297-300..
50. Ikagawa H，Yoneda M，Iwaki M，et al.Chemical toxicity of indocyanine green damages retinal pigment epithelium[J].Invest Ophthalmol Vis Sci，2005,46(7)：2531-2539..
51. Yamamoto T，Hitani K，Sato Y，et al.Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema[J].Ophthalmologica，2005，219(4)：206-213..
52. Jonas JB，Kreissig I，Sofker A，et al.Intravitreal injection of triamcinolone for diffuse diabetic macular edema[J].Arch Ophthalmol，2003，121(1)：57-61..
53. Martidis A，Duker JS，Greenberg PB，et al，Baumal C.Intravitreal triamcinolone for refractory diabetic macular edema[J].Am J Ophthalmol，2002，109(5)：920-927..
54. 姚毅，王志军，姜荔，等.玻璃体内注射曲安奈德治疗糖尿病性弥漫性黄斑水肿的初步观察[J].中华眼底病杂志，2005，21(4)：217-219..
55. Bandello F，Polito A，Pognuz DR，et al.Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy[J].Arch Ophthalmol，2006，124(5)：643-650..
56. Zacks DN，Johnson MW.Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy[J].Retina，2005，25(2)：135-140..
57. Smithen LM，Ober MD，Maranan L，et al.Intravitreal triamcinolone acetonide and intraocular pressure[J].Am J Ophthalmol，2004，138(5)：740-743..
58. Quiram PA，Gonzales CR，Schwartz SD.Severe steroidinduced glaucoma following intravitreal injection of triamcinolone acetonide[J].Am J Ophthalmol，2006，141(3)：580-582..
59. Kaushik S，Gupta V，Gupta A，et al.Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion[J].Am J Ophthalmol，2004，137(4)：758-760..
60. Thompson JT.Cataract formation and other complications of intravitreal triamcinolone for macular edema[J].Am J Ophthalmol，2006，141(4)：629-637..
61. Kuppermann BD，Blumenkranz MS，Haller JA，et al.Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema[J].Arch Ophthalmol，2007，125(3)：309-317..
62. Tilton RG，Kawamura T，Chang KC，et al.Vascular dysfunction induced by elevated glucose levels in rats mediated by vascular endothelial growth factor[J].J Clin Invest，1997，99(9)：2192-2202..
63. Ferrara N.Vascular endothelial growth factor：basic science and clinical progress[J].Endocr Rev，2004，25(4)：581-611..
64. Tolentino MJ，Miller JW，Gragoudas ES，et al.Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate[J].Ophthalmology，1996，103(11)：18201828..
65. Tolentino MJ，McLeod DS，Taomoto M.Pathologic features of vascular endothelial growth factorinduced retinopathy in the nonhuman primate[J].Am J Ophthalmol，2002，133(3)：373-385..
66. Adamis AP，Shima DT，Tolentino MJ，et al.Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate[J].Arch Ophthalmol，1996，114(1)：6671..
67. Aiello LP，Pierce EA，Foley ED，et al.Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor(VEGF)using soluble VEGFreceptor chimeric proteins[J].Proc Natl Acad Sci USA，1995，92(23)：10457-10461..
68. Jorge R，Costa RA，Calucci D，et al.Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)[J].Retina，2006，26(9)：1006-1013..
69. Ferrara N，Houck KA，Jakeman LB，et al.The vascular endothelial growth factor family of polypeptides[J].J Cell Biochem，1991，47(3)：211-218..
70. Spaide RF，Fisher YL.Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage[J].Retina,2006，26(3)：275-278..
71. Michels S，Rosenfeld PJ，Puliafito CA，et al.Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration. Twelveweek results of an uncontrolled openlabel clinical study[J].Ophthalmology，2005，112(6)：1035-1047..
72. Avery RL，Pieramici DJ，Rabena MD，et al.Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration[J].Ophthalmology，2006，113(3)：363-372..
73. Iturralde D，Spaide RF，Meyerle CB.Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion：a shortterm study[J].Retina，2006，26(3)：279-284..
74. Diabetic Retinopathy Clinical Research Network (DRCR.net)，a phase 2 randomized clinical trial of intravitreal Bevacizumab for diabetic macular edema[J].Ophthalmology，2007，114(10)：1860-1867..
75. Rosenfeld PJ，Brown DM，Heier JS，et al，MARINA Study Group.Ranibizumab for neovascular agerelated macular degeneration[J].N Engl J Med，2006，355(14)：14191431..
76. Brown DM，Kaiser PK，Michels M，et al，ANCHOR Study Group.Ranibizumab versus verteporfin for neovascular agerelated macular degeneration[J]. N Engl J Med，2006，355(14)：1432-1444..
77. Chun DW，Heier JS，Topping TM，et al.A pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema[J]. Ophthalmology，2006，113(10)：1706-1712..
78. Nguyen QD，Tatlipinar S，Shah SM，et al.Vascular endothelial growth factor is a critical stimulus for diabetic macular edema[J].Am J Ophthalmol，2006，142(6)：961-969..
79. Koya D，King GL.Protein kinase C activation and the development of diabetic complications[J].Diabetes，1998，47(6)：859-866..
80. Nagpala P，Malik AB，Vuong PT，et al.Protein kinase Cb1 overexpression augments phorbol esterinduced increase in endothelial permeability[J].J Cell Physiol，1996，166：249-255..
81. Xia P，Aiello LP，Ishii H.Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C，its isoforms，and endothelial cell growth[J].J Clin Invest，1996，98：2018-2026..
82. Xu X，Qi Z，Xin X，et al.Bloodretinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocininduced diabetic rats[J].Curr Eye Res，2004，28(4)：251256..
83. Zhu Q，Xu X，Xia X，et al.Role of protein kinase C on the alteration of retinal endothelin1 in streptozotocininduced diabetic rats[J].Exp Eye Res，2005，81(2)：200-206..
84. Jirousek MR，Gillig JR，Gonzalez CM，et al.(S)13[(dimethylamino)methyl]10，11，14，15tetrahydro4，9：16，21dimetheno1H，13Hdibenzo[e，k]pyrrolo[3，4h][1，4，13]oxadiazacyclohexadecene1，3(2H)dione(LY333531)and related analogues：isozyme selective inhibitors of protein kinase C[J].J Med Chem，1996，39(14)：26642671..
85. The PKCDRS Study Group，The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy：initial results of the protein kinaseC inhibitor diabetic retinopathy study (PKCDRS) multicenter randomized clinicaltrial[J].Diabetes，2005，54(7)：2188-2197..
86. PKCDRS2 Group，Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy[J].Ophthalmology，2006，113(12)：2221-2230..
87. The PKCDMES Study Group，Effect of ruboxistaurin in patients with diabetic macular edema：thirtymonth results of the randomized PKCDMES clinical trial[J].Arch Ophthalmol，2007，125(3)：318-324..
88. Strm C，Sander B，Klemp K，et al.Effect of ruboxistaurin on bloodretinal barrier permeability in relation to severity of leakage in diabetic macular edema[J].Invest Ophthalmol Vis Sci，2005，46(10)：38553888..
89. The PKCDRS Study Group.The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy：initial results of the protein kinase C β inhibitor Diabetic Retinopathy Study (PKCDRS) multicentre randomized clinical trial[J].Diabetes，2005，54(7)：2188-2197..
90. Aiello LP，Vignati L，Sheetz MJ.Effect of ruboxistaurin (RBX) on diabetic macular edema (DME) and visual loss：Metaanalysis of the PKCDRS and PKCDRS2[J].Diabetes，2006，55(S1)：54..
91. Schwartz SG，Flynn HW.Pharmacotherapies for diabetic retinopathy：present and future[J].Exp Diabetes Res，2007，2007：52487..

West China Medical Journal

糖尿病黄斑水肿：发病机制及治疗进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content